Roche Acquiring Santaris Pharma for Up to $450 Million

Roche said Tuesday it will acquire Santaris Pharma for up-to-$450 million, some seven months after the pharma giant and Danish-based biotech launched an up-to-$148 million-plus-per-product alliance designed to discover and develop RNA-targeted oligonucleotide therapeutics using Santaris’ locked nucleic acid (LNA) drug platform.
GEN